SCHEMBL497459

SCHEMBL497459

COC(=O)c1cn(S(=O)(=O)c2ccccc2)c2ncccc12

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HTR6 P50406 1/20 0.51
PTGDR2 Q9Y5Y4 3/20 0.49
SLC40A1 Q9NP59 1/20 0.48
PLK1 P53350 1/20 0.48
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 2/20 0.46
MAP2K1 Q02750 1/20 0.44
CCNE1 P24864 2/20 0.43
CDK2 P24941 2/20 0.43
NR4A2 P43354 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 1/20 0.42
BRD4 O60885 1/20 0.42
MAPK8 P45983 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26625068 0.82 HTR6 (0.50) MEN1KMT2ALMNASMN1; SMN2HTR6
SCHEMBL13613784 0.81 KMT2A (0.59) MEN1KMT2ALMNASMN1; SMN2HTR6
SCHEMBL1894844 0.81 MEN1 (0.59) MEN1KMT2ALMNASMN1; SMN2HTR6
SCHEMBL2886421 0.81 KMT2A (1.00) MEN1KMT2ALMNASMN1; SMN2HTR6
SCHEMBL496782 0.78 MEN1 (0.55) MEN1KMT2ALMNASMN1; SMN2PTGDR2
SCHEMBL1773129 0.78 HTR6 (0.58) LMNASMN1; SMN2HTR6PTGDR2SLC40A1
SCHEMBL2984205 0.78 L3MBTL1 (0.55) LMNASMN1; SMN2HTR6PTGDR2KDM4E
SCHEMBL17394567 0.77 HTR6 (0.58) MEN1KMT2ALMNASMN1; SMN2HTR6
SCHEMBL28207078 0.76 KMT2A (0.76) MEN1KMT2ALMNASMN1; SMN2HTR6
SCHEMBL1267767 0.76 CYP2C19 (0.56) LMNASMN1; SMN2HTR6PTGDR2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198298-B2 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2012-06-12 US disclosed
US-8106069-B2 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2012-01-31 US disclosed
US-20110136857-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS PFIZER ITALIA S.R.L. (IT) 2011-06-09 US disclosed
US-7888508-B2 3-(carboxy or carbamoyl)-5-amino-1H-pyrrolo(2,3-b)pyridines; cancer, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders; chemical libraries of these compounds PFIZER ITALIA S.R.L. (IT) 2011-02-15 US disclosed
US-20100210476-A1 Pyrrolo[2,3-b]Pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them PFIZER ITALIA S.R.L. (IT) 2010-08-19 US disclosed
US-7728140-B2 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2010-06-01 US disclosed
EP-1701956-B1 PYRROLO[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2010-02-24 EP disclosed
EP-1704147-B1 PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM PFIZER ITALIA SRL (IT) 2009-11-04 EP disclosed
EP-1704147-A1 PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM Pfizer Italia S.r.l. (IT) 2006-09-27 EP disclosed
EP-1701956-A1 PYRROLO[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pfizer Italia S.r.l. (IT) 2006-09-20 EP disclosed
US-20050256151-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-11-17 US disclosed
US-20050209269-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-09-22 US disclosed
WO-2005063747-A1 PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM PFIZER ITALIA S.R.L. (IT) 2005-07-14 WO disclosed
WO-2005063746-A1 PYRROLO[2,3-b]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA S.R.L. (IT) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210476-A1 Pyrrolo[2,3-b]Pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them MAP3K6, MAP3K3, MAP3K1 MEN1 2558/4885KMT2A 1717/4885LMNA 4001/4885
US-20050256151-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K6, MAP3K3, MAP3K1 MEN1 2469/4885KMT2A 1599/4885LMNA 3842/4885
US-20110136857-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K6, MAP3K3, MAP3K15 MEN1 2478/4885KMT2A 1503/4885LMNA 4426/4885
US-20050209269-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K6, MAP3K3, MAP3K1 MEN1 2469/4885KMT2A 1599/4885LMNA 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.